Humanized anti-Lymphotoxin beta receptor antibodies
AssigneeBiogen Idec MA Inc.
InventorsEllen Garber, Kenneth Simon, Jose Saldanha
Life of this patent
Estimating the term…
Abstract
This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.
Claims32
A humanized anti-lymphotoxin-beta receptor (LT-β-R) antibody, or antigen-binding fragment thereof, whose light chain complementary determining regions are defined by amino acid residues 24 to 34, 50 to 56 and 89 to 97 of SEQ ID NO:1, and whose heavy chain complementary determining regions are defined by amino acid residues 31 to 35, 50 to 65 and 95 to 102 of SEQ ID NO:
- 2 and wherein the antibody comprises at least one of the following residues in its light chain:
- Y36, S49, T63 and F87;
- or at least one of the following residues in its heavy chain:
- Y27, T30, I48, A67, L69 and F91 (Kabat numbering convention).
A humanized anti-lymphotoxin-beta receptor (LT-β-R) antibody, or antigen-binding fragment thereof, whose light chain complementary determining regions are defined by amino acid residues 24 to 34, 50 to 56 and 89 to 97 of SEQ ID NO:1, and whose heavy chain complementary determining regions are defined by amino acid residues 31 to 35, 50 to 65 and 95 to 102 of SEQ ID NO:
- 2, wherein the antibody comprises residue Y36, S49 and F87 in its light chain (Kabat numbering convention) or residue Y27 and T30 in its heavy chain (Kabat numbering convention).
An antibody, or antigen-binding fragment thereof, comprising the same heavy and light chain polypeptide sequences as an antibody produced by cell line:
- Clone 3D9 (ATCC patent deposit designation PTA-4726, deposited on Sep. 27, 2002).
A method of either treating or reducing the advancement, severity or effects of neoplasia in a human or reducing tumor volume in a human comprising administering the composition of claim 14 to said human.
An isolated nucleic acid comprising either a coding sequence for a light chain of an antibody produced by cell line:
- Clone 3D9 (ATCC patent deposit designation PTA-4726, deposited on Sep. 27, 2002) or a heavy chain of an antibody produced by cell line:
- Clone 3D9 (ATCC patent deposit designation PTA-4726, deposited on Sep. 27, 2002).
An isolated nucleic acid comprising a coding sequence for residues 1 to 107 of SEQ ID NO:5 or residues 1 to 113 of SEQ ID NO:13.
A hybridoma cell consisting of 3D9 (ATCC Accession No. PTA-4726).
A light chain comprising the complementarity determining regions (CDRs) and variable region framework amino acid residues Y36, S49, and F87 (Kabat numbering system) from SEQ ID NO:1, wherein the remainder of the light chain is from a human antibody.
A heavy chain comprising the complementarity determining regions (CDRs) and variable region framework amino acid residues Y27 and T30 (Kabat numbering system) from SEQ ID NO:
- 2, wherein the remainder of the heavy chain is from a human antibody.
A humanized antibody, or antigen-binding fragment thereof, which specifically binds LT-β-R, comprising a variable region comprising CDRs corresponding to CDRs from the mouse BHA10 antibody.
Dependencies are inferred from the claim text.